Table 1.
Baseline characteristics of study population according to treatment.
| Variables | Sacubitril/Valsartan (n = 12) | Control Group (n = 13) | p Value |
|---|---|---|---|
| Demographic and clinical data | |||
| Age (years) | 66.1 ± 7.9 | 60.8 ± 7.4 | 0.1 |
| Female Gender N (%) | 2 (16.7) | 2 (15.4) | 0.9 |
| BMI (Kg/m2) | 28.4 ± 4.3 | 27.4 ± 3.0 | 0.5 |
| SBP (mmHg) | 110 (110–130) | 115 (110–125) | 0.8 |
| HR (beats/min) | 70 (60–74) | 60.5 (57.2–68.5) | 0.2 |
| NYHA Class | |||
| 2 | 8 (66.7) | 9 (69.2) | 0.6 |
| 3 | 4 (33.3) | 3 (23.1) | |
| 4 | 0 | 1 (7.7) | |
| Laboratory data | |||
| Haemoglobin (g/dL) | 14.7 (11.8–15.5) | 14.3 (10.6–14.8) | 0.3 |
| Fasting glucose (mg/dL) | 110 (92–121) | 103 (93.5–111.5) | 1 |
| Creatinine (mg/dL) | 1 (0.9–1.19) | 1.06 (0.94–1.21) | 0.7 |
| Potassium (mEq/L) | 4.36 ± 0.8 | 4.4 ± 0.74 | 0.8 |
| eGFR (mL/min) | 70.1 ± 20.6 | 72.5 ± 32.0 | 0.8 |
| LDL (mg/dL) | 86.4 ± 32.0 | 87.5 ± 33.4 | 0.9 |
| Tryglicerides (mg/dL) | 156.5 ± 74.3 | 104.7 ± 36.7 | 0.1 |
| Comorbidities | |||
| Coronary artery disease N (%) | 8 (66.7) | 5 (38.5) | 0.2 |
| Primitive dilated cardiomyopathy N (%) | 3 (25) | 6 (46.2) | 0.4 |
| Hypertension N (%) | 10 (83.3) | 9 (69.2) | 0.6 |
| Dyslipidemia N (%) | 12 (100) | 11 (84.6) | 0.5 |
| Atrial fibrillation N (%) | 5 (41.7) | 2 (15.4) | 0.2 |
| Diabetes N (%) | 5 (41.7) | 2 (15.4) | 0.2 |
| Chronic Kidney Disease N (%) | 6 (50) | 8 (61.5) | 0.7 |
| Chronic obstructive pulmonary disease N (%) | 0 | 5 (38.5) | 0.04 |
| Thyroid disorders N (%) | 4 (33.3) | 2 (15.4) | 0.4 |
| Previous implantation of ICD/CRT N (%) | 11 (91.7) | 10 (76.9) | 0.6 |
| Medications N (%) | |||
| β-blockers (bisoprolol) | 12 (100) | 13 (100) | - |
| Furosemide | 11 (91.7) | 12 (92.3) | 0.95 |
| Mineralcorticoid receptor antagonist (MRA) | 11 (91.7) | 12 (92.3) | 0.95 |
| Medications dose (mg) | |||
| Bisoprolol | 2.5 (2.5–3.75) | 2.5 (1.25–4.37) | 0.79 |
| Furosemide | 50 (25–68.7) | 50 (25–75) | 0.84 |
| MRA | 37.5 (25–50) | 25 (25–50) | 0.63 |
BMI: body mass index; SBP: systolic blood pressure; HR: heart rate; NYHA: New York Heart Association; eGFR: estimated glomerular filtration rate; LDL: low-density lipoproteins; ICD: implantable cardioverter defibrillator; CRT: cardiac resynchronization therapy; MRA: mineralocorticoid receptor antagonist. We have reported in bold the statistically significant p-value.